Dr John Maher
Consultant and Senior Lecturer in Immunology
Research interests
- Cancer
- Immunology
Contact details
Biography
Dr John Maher is a Senior Lecturer within the Comprehensive Cancer Centre.
Research
CAR Mechanics Group
The CAR Mechanics Group originated in 2004 and has sought to develop and translate novel CAR T-cell strategies for the treatment of patients with refractory solid tumours. We have developed several experimental CAR approaches in addition to ancillary technologies that enable improved CAR T-cell expansion and homing to sites of disease. The CAR Mechanics group has advanced one candidate named T4 immunotherapy to Phase 1 clinical trial evaluation with funding from the Jon Moulton Charitable Foundation, Wellcome Trust and the Biomedical Research Centre at Guy’s and St Thomas’ NHS Foundation Trust.
Experimental Oncology
The Experimental Oncology Programme is focused on the development of new treatments for solid tumours.
Project status: Ongoing
Cancer Immunology & Immunotherapy
Cancer Immunology represents a broad field of research that studies host-tumour interactions as therapeutic targets in the treatment of cancer.
Project status: Ongoing
News
Leucid Bio gains clinical trial approval for new CAR-T Cell Therapy
The King’s spin-out will dose its first patients by the end of 2023 in order to test its new CAR-T Cell Therapy, designed for the treatment of adults with...
New papers give fresh promise for CAR T-cell cancer immunotherapy
The two studies, published in Cell Reports Medicine and Froniters in Immunology, have provided new insights into a specific type of CAR T-cell immunotherapy...
CAR-T therapy modifications provides new promise for cancer immunotherapies
Researchers from King’s and Leucid Bio have made additional modifications to CAR T-cells receptors, in collaboration with LUMICKS, improving its therapeutic...
King's spin out Leucid Bio wins funding boost for CAR-T therapies
Researchers developing pioneering cell therapies for hard-to-treat cancers have received a significant funding boost.
Engineering T-cells to selectively target cancer
Researchers from the Faculty of Life Sciences & Medicine have re-designed the genetic code of cells which can be trained to aggressively attack solid...
Events
CAR T-cell immunotherapy of solid tumours – learning from the clinic and lab in parallel
Speaker: John Maher, Division of Cancer Studies, King's College London
Please note: this event has passed.
Features
Transforming cancer care at King's
King’s is the site of future breakthroughs, transforming cancer care and therapies through innovative research. An injection of philanthropic donations...
Spotlight
How King's continues to tackle cancer and support cancer care and research
Saturday 4 February marks World Cancer Day. In order to honour this key date, we have highlighted some of the most important cancer-themed stories that have...
Research
CAR Mechanics Group
The CAR Mechanics Group originated in 2004 and has sought to develop and translate novel CAR T-cell strategies for the treatment of patients with refractory solid tumours. We have developed several experimental CAR approaches in addition to ancillary technologies that enable improved CAR T-cell expansion and homing to sites of disease. The CAR Mechanics group has advanced one candidate named T4 immunotherapy to Phase 1 clinical trial evaluation with funding from the Jon Moulton Charitable Foundation, Wellcome Trust and the Biomedical Research Centre at Guy’s and St Thomas’ NHS Foundation Trust.
Experimental Oncology
The Experimental Oncology Programme is focused on the development of new treatments for solid tumours.
Project status: Ongoing
Cancer Immunology & Immunotherapy
Cancer Immunology represents a broad field of research that studies host-tumour interactions as therapeutic targets in the treatment of cancer.
Project status: Ongoing
News
Leucid Bio gains clinical trial approval for new CAR-T Cell Therapy
The King’s spin-out will dose its first patients by the end of 2023 in order to test its new CAR-T Cell Therapy, designed for the treatment of adults with...
New papers give fresh promise for CAR T-cell cancer immunotherapy
The two studies, published in Cell Reports Medicine and Froniters in Immunology, have provided new insights into a specific type of CAR T-cell immunotherapy...
CAR-T therapy modifications provides new promise for cancer immunotherapies
Researchers from King’s and Leucid Bio have made additional modifications to CAR T-cells receptors, in collaboration with LUMICKS, improving its therapeutic...
King's spin out Leucid Bio wins funding boost for CAR-T therapies
Researchers developing pioneering cell therapies for hard-to-treat cancers have received a significant funding boost.
Engineering T-cells to selectively target cancer
Researchers from the Faculty of Life Sciences & Medicine have re-designed the genetic code of cells which can be trained to aggressively attack solid...
Events
CAR T-cell immunotherapy of solid tumours – learning from the clinic and lab in parallel
Speaker: John Maher, Division of Cancer Studies, King's College London
Please note: this event has passed.
Features
Transforming cancer care at King's
King’s is the site of future breakthroughs, transforming cancer care and therapies through innovative research. An injection of philanthropic donations...
Spotlight
How King's continues to tackle cancer and support cancer care and research
Saturday 4 February marks World Cancer Day. In order to honour this key date, we have highlighted some of the most important cancer-themed stories that have...